{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.737","value":"-0.15"},{"groupId":"OG001","spread":"0.910","value":"-0.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total BASMI score ranging from 0 to 10. The higher the BASMI score, the more severe was the participant's limitation of movement due to their AS.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.","id":"OG000","title":"Group 1: Placebo Then Golimumab"},{"description":"Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.","id":"OG001","title":"Group 2: Golimumab"}],"paramType":"MEAN","populationDescription":"FAS included all participants who were randomized in the study. Here, 'N' (Number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 16","title":"Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 16","type":"SECONDARY","unitOfMeasure":"Units on Scale"}